Chimeric Therapeutics Ltd
CHM
Company Profile
Business description
Chimeric Therapeutics Ltd is a biotechnology company engaged in developing a cancer cell therapy drug. Its technology CLTX-CAR T uses chlorotoxin, a peptide discovered in scorpion venom, as the tumor-targeting component of the CAR to reprogram T cells. Primary products under development by the company are NK Cell Derived Allogenic Therapies and T Cell Derived Autologous Therapies. The company has one segment being the research, development and commercialization of health technologies.
Contact
62 Lygon Street
Level 3, Carlton South
MelbourneVIC3053
AUST: +61 398245254
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2025
Employees
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,421.70 | 21.90 | 0.26% |
| CAC 40 | 7,690.33 | 63.49 | 0.83% |
| DAX 40 | 23,291.47 | 175.51 | 0.76% |
| Dow JONES (US) | 41,339.89 | 225.92 | 0.55% |
| FTSE 100 | 8,529.42 | 29.91 | -0.35% |
| HKSE | 22,775.92 | 84.04 | 0.37% |
| NASDAQ | 17,879.28 | 141.12 | 0.80% |
| Nikkei 225 | 36,928.63 | 148.97 | 0.41% |
| NZX 50 Index | 12,467.03 | 29.86 | -0.24% |
| S&P 500 | 5,663.71 | 32.43 | 0.58% |
| S&P/ASX 200 | 8,191.70 | 13.40 | 0.16% |
| SSE Composite Index | 3,352.00 | 9.33 | 0.28% |